| Informacje o ameliataylor0305 |
| Dołączył: |
26-06-2021 |
| Ostatnia wizyta: |
26-06-2021, 09:58 |
| Razem postów: |
0 (0 postów dziennie | 0 procent wszystkich postów) |
| Razem wątków: |
0 (0 wątków dziennie | 0 procent wszystkich wątków) |
| Spędzony czas online: |
1 Minuta, 24 Sekund |
|
|
| Dodatkowe informacje o ameliataylor0305 |
| Sex: |
Male |
| Location: |
usa |
| Bio: |
The drug Abiraterone 250 mg (Zytiga) reduces the concentration of testosterone and other androgens in the serum below those values that can be obtained with the use of lu-liberin agonists or after orchidectomy. This is due to the selective inhibition of the CYP17 enzyme, which is required for androgen biosynthesis. The concentration of prostate-specific antigen (PSA) serves as a biomarker in patients with prostate cancer. Mechanism of action Abiraterone acetate in vivo is converted to Zytiga, which is an inhibitor of androgen biosynthesis. In particular, Zytiga selectively inhibits the activity of the 17α-hydroxylase / C17,20-lyase (CYP17) enzyme. This enzyme is expressed and is required for the biosynthesis of androgens in the testes, adrenal glands and prostate tumor cells. CYP17 catalyzes the conversion of pregnenolone and progesterone by 17α-hydroxylation and cleavage of the C17,20 bond to testosterone precursors: dehydroepiandrosterone and androstenedione, respectively. Inhibition of CYP17 activity is also accompanied by an increase in the synthesis of mineralocorticoids in the adrenal glands. Androgen-sensitive prostate cancer responds to androgen-lowering treatments. Anti-androgen therapy, such as the use of lu-liberin agonists or orchiectomy, attenuates androgen synthesis in the testes, but does not affect androgen synthesis in the adrenal glands and in the tumor. The use of Abiraterone 250 mg (Zytiga) in conjunction with lu-liberin agonists (or orchidectomy) reduces the serum testosterone concentration to a level below the detection threshold. dehydroepiandrosterone and androstenedione, respectively. Inhibition of CYP17 activity is also accompanied by an increase in the synthesis of mineralocorticoids in the adrenal glands. Androgen-sensitive prostate cancer responds to androgen-lowering treatments. Anti-androgen therapy, such as the use of lu-liberin agonists or orchiectomy, attenuates androgen synthesis in the testes, but does not affect androgen synthesis in the adrenal glands and in the tumor. The use of Abiraterone 250 mg (Zytiga) in conjunction with lu-liberin agonists (or orchidectomy) reduces the serum testosterone concentration to a level below the detection threshold. dehydroepiandrosterone and androstenedione, respectively. Inhibition of CYP17 activity is also accompanied by an increase in the synthesis of mineralocorticoids in the adrenal glands. Androgen-sensitive prostate cancer responds to androgen-lowering treatments. Anti-androgen therapy, such as the use of lu-liberin agonists or orchiectomy, attenuates androgen synthesis in the testes, but does not affect androgen synthesis in the adrenal glands and in the tumor. The use of Abiraterone 250 mg (Zytiga) in conjunction with lu-liberin agonists (or orchidectomy) reduces the serum testosterone concentration to a level below the detection threshold. Androgen-sensitive prostate cancer responds to androgen-lowering treatments. Anti-androgen therapy, such as the use of lu-liberin agonists or orchiectomy, attenuates androgen synthesis in the testes, but does not affect androgen synthesis in the adrenal glands and in the tumor. The use of Abiraterone 250 mg (Zytiga) in conjunction with lu-liberin agonists (or orchidectomy) reduces the serum testosterone concentration to a level below the detection threshold. Androgen-sensitive prostate cancer responds to androgen-lowering treatments. Anti-androgen therapy, such as the use of lu-liberin agonists or orchiectomy, attenuates androgen synthesis in the testes, but does not affect androgen synthesis in the adrenal glands and in the tumor. The use of Zytiga 250 mg in conjunction with lu-liberin agonists (or orchidectomy) reduces the serum testosterone concentration to a level below the detection threshold.
|
|
